Showing 81-90 of 454 results
In the presence of Mr. Christian Vitta, Director of the Finance and Economic Department, Mr. Manuele Bertoli, Director of the Department of Education, Culture and Sport, and of Biasca’s Town Mayor, Mr. Jean-François Dominé, on Friday November 20th, 11 students were awarded an “Helsinn Advanced Synthesis” Educational Scholarship in the chemical and pharmaceutical sectors for the...
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency (EMA) accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small...
Helsinn, the Swiss Group focused on building quality in cancer care, and Vifor Pharma, announced today that Swissmedic, the Swiss Agency For Therapeutic Products, has approved Akynzeo® (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adults. The approval was granted on 6th November 2015.
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is delighted to launch its 40th anniversary celebrations in San Francisco, US, at the time of the JP Morgan 34th Annual Healthcare Conference. Helsinn believes its core values of respect, integrity and quality have underpinned four decades of progress in helping patients enjoy a better quality of l...
This exclusive agreement strengthens previous alliances with Mundipharma and its network of independent associated companies in cancer supportive care across multiple territories worldwide
Helsinn Therapeutics Inc. to obtain all rights to promote and distribute AKYNZEO® (netupitant/palonosetron) Eisai and Helsinn to continue to co-promote and distribute ALOXI® (palonosetron HCl) injection
Pivotal data from anamorelin ROMANA 1 and ROMANA 2 Phase III studies published in world-leading, peer-reviewed medical journal Study showed anamorelin significantly improved lean body mass, body weight and symptom burden including appetite in NSCLC patients with cachexia
Helsinn Group is pleased to present its first group sustainability report, Quality of Life, demonstrating that being a good corporate citizen is at the heart of everything we do.
Helsinn wins in five categories; Quality, Reliability, Capabilities, Expertise and Compatibility, earning a place among the best in the industry, and also wins Individual Attribute Awards in the categories: Accessible Senior Management; State-of-the-Art; Innovation; Right the First Time; Strength of Science; On Time Delivery; Cultural Fit; and Reputation
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, announces that it is supporting the NCCN Foundation® in the development of NCCN Guidelines for Patients® and a correspondent NCCN Quick Guide™, patient education materials on the management of nausea and vomiting through a sponsorship grant.